Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is expected to report third quarter earnings results, after market close, on Monday 9th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter income of $ 0.22 per share.
Looking ahead, the full year income are expected at $ 2.38 per share on the revenues of $ 1129.36 million.
Previous Quarter Performance
Neurocrine Biosciences, Inc. communicated income for the second quarter of $ 1.42 per share, from the revenue of $ 302.40 million. The quarterly earnings swell 162.96 percent while revenues improved 64.72 percent compared with the same quarter last year.
According to street consensus, NBIX was expected to report 2Q20 income of $ 0.73 per share from revenue of $ 260.52 million. The bottom line results beat street analysts by $ 0.69 or 94.52 percent, at the same time, top line results outshined analysts by $ 41.88 million or 16.08 percent.
Stock Performance
On Friday, shares of Neurocrine Biosciences, Inc. has traded high as $ 100.15 and has cracked $ 94.85 on the downward trend, reaching $ 96.34 with volume of 2.17 million shares.
According to the previous trading day, closing price of $ 96.34, representing a 39.06 % increase from the 52 week low of $ 72.14 and a 26.38 % decrease over the 52 week high of $ 136.26.
The company has a market capital of $ 8.98 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 30th September 2020, initiated by Benchmark at Hold rating.
Conference Call
Neurocrine Biosciences, Inc. will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.neurocrine.com
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in womens health.
